Novel therapeutic strategies for treatment of Angelman Syndrome

治疗天使综合症的新治疗策略

• 批准号: 7774411
• 负责人: Edwin John Weeber
• 金额: $ 22.05万
• 依托单位: UNIVERSITY OF SOUTH FLORIDA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-26 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7774411
• 关键词: Ablation; Acute; Address; Adult; Age; Angelman Syndrome; Area; Ataxia; Autistic Disorder; Bilateral; Biochemical; Brain region; Calcium; Cognition Disorders; Cognitive; Defect; Deletion Mutation; Dependovirus; Disease; Effectiveness; Elderly; Engineering; Enhancers; Etiology; Exhibits; Frequencies; Functional disorder; Future; Gene Expression; Genes; Genetic; Goals; Hippocampus (Brain); Human; Human Development; Impaired cognition; Independent Living; Individual; Injection of therapeutic agent; Intervention; Learning; Measures; Mental Retardation; Methylation; Molecular; Molecular Abnormality; Molecular Target; Mus; Mutant Strains Mice; N-Methyl-D-Aspartate Receptors; Neonatal Screening; Phenotype; Phosphorylation; Pilot Projects; Population; Principal Investigator; Proteins; Research Personnel; Research Project Grants; Rett Syndrome; Seizures; Site; Slice; Speech; Stream; Synapses; Synaptic plasticity; Testing; Therapeutic; Therapeutic Human Experimentation; Therapeutic Intervention; Threonine; Transfection; Virus; base; calmodulin-dependent protein kinase II; design; effective therapy; fusion gene; gene replacement; imprint; maternal imprint; mouse model; nervous system disorder; novel therapeutics; particle; postnatal; pre-clinical; programs; receptor; receptor function; reelin protein; synaptic function; treatment strategy; virtual

DESCRIPTION (Provided by Applicant): Angelman syndrome (AS) is a genetic neurological disorder that presents with seizure, ataxia, severe mental retardation, virtual absence of speech, and is genetically and biochemically associated with other cognitive disorders, such as autism and Rett syndrome. This project is designed with the ultimate goal of establishing the basis for future rational development of human AS interventions. The investigators present evidence which indicates that AS is potentially a treatable disorder. This exciting possibility is experimentally testable due in large part to the extraordinary utility of the Ube3am-/p+ mouse model. They have developed three distinct therapeutic interventions to determine if the Ube3am-/p+ mouse model phenotype can be rescued in a postnatal fashion through intervention (1) at the site of genetic abnormality, (2) at the downstream biochemical site of dysfunction, or (3) by directly modifying synaptic function. Because the availability of an effective treatment is often a criterion for inclusion of a condition on a newborn screening panel, their goal is to establish the preclinical viability of these therapeutic strategies, determine the temporal constraints for treatment, and identify the optimal molecular targets for future human therapeutic research. PROJECT NARRATIVE: Angelman syndrome (AS) is a genetic neurological disorder occurring in one in 12,000 population. Independent living is not possible for adults with AS. The goals of this project are to establish the viability of three distinct therapeutic strategies to ameliorate the severe cognitive impairments exhibited by AS individuals.

描述（由申请人提供）：Angelman综合征（AS）是一种遗传性神经障碍，其表现为癫痫发作、共济失调、严重精神发育迟滞、实际言语缺失，并且在遗传和生物化学上与其他认知障碍（例如自闭症和Rett综合征）相关。 该项目的最终目标是为人类AS干预措施的未来合理发展奠定基础。 研究人员提出的证据表明，AS是一种潜在的可治疗的疾病。 这种令人兴奋的可能性在实验上是可以测试的，这在很大程度上是由于Ube 3am-/p+小鼠模型的非凡实用性。 他们开发了三种不同的治疗干预措施，以确定Ube 3am-/p+小鼠模型表型是否可以通过干预（1）遗传异常部位，（2）功能障碍的下游生化部位，或（3）直接修饰突触功能以出生后的方式进行挽救。 由于有效治疗的可用性通常是新生儿筛查小组纳入条件的标准，因此他们的目标是建立这些治疗策略的临床前可行性，确定治疗的时间限制，并确定未来人类治疗研究的最佳分子靶点。 项目叙述：安格尔曼综合征（AS）是一种遗传性神经系统疾病，每12，000人中就有1人发生。 成人AS患者不可能独立生活。 本项目的目标是建立三种不同的治疗策略，以改善AS个体表现出的严重认知障碍的可行性。